#1 Clinical Trials Search in Europe

TAZAROTENE

Tazarotene is a synthetic retinoid medication that has been extensively studied in clinical trials for various dermatological conditions. This powerful topical treatment works by normalizing skin cell growth and reducing inflammation. Clinical trials have investigated tazarotene in different formulations (creams, gels, foams, and lotions) and concentrations (primarily 0.05% and 0.1%) for conditions including acne vulgaris, plaque psoriasis, and other skin disorders. This article examines the evidence from clinical trials regarding tazarotene’s effectiveness, safety profile, and application methods to help patients better understand this treatment option.

Table of Contents

What is Tazarotene?

Tazarotene is a prescription medication that belongs to a class of drugs known as retinoids, which are related to vitamin A. Specifically, it is classified as an acetylenic retinoid, which means it has a particular chemical structure that makes it effective for certain skin conditions. Tazarotene is available under various brand names, including Tazorac®, Fabior™, and Arazlo™, among others [1].

How Does Tazarotene Work?

Tazarotene works by normalizing skin cell development and reducing inflammation. When applied to the skin, tazarotene is converted to its active form, tazarotenic acid, which then binds to specific receptors in skin cells. This binding action helps to:

  • Normalize the way skin cells grow and develop
  • Reduce the influx of inflammatory cells into the skin
  • Promote the shedding of dead skin cells, preventing pore blockage
  • Stimulate collagen production, which may help with certain types of scarring

By affecting these processes, tazarotene can help manage various skin conditions characterized by abnormal skin cell growth or inflammation [2].

Conditions Treated with Tazarotene

Clinical trials have shown that tazarotene is effective in treating several skin conditions:

Acne Vulgaris

Acne vulgaris is a common skin condition characterized by comedones (blackheads and whiteheads), inflammatory lesions (papules, pustules, and nodules), and sometimes scarring. Tazarotene has been extensively studied for treating moderate to severe acne [3].

Plaque Psoriasis

Plaque psoriasis is a chronic autoimmune condition characterized by raised, red, scaly patches on the skin. Tazarotene helps reduce the thickness, scaling, and redness of psoriatic plaques [1].

Other Skin Conditions

Clinical trials have also investigated tazarotene for treating:

  • Basal cell carcinoma (BCC) and basal cell nevus syndrome (BCNS): Studies have examined tazarotene’s potential as a chemopreventive agent for these conditions [4].
  • Brittle nails: Tazarotene may help improve the condition of brittle fingernails [2].
  • Atrophic post-acne scarring: Research suggests tazarotene might help improve the appearance of acne scars [5].
  • Cutaneous T-cell lymphoma: Tazarotene has been studied as a treatment for this rare type of skin cancer [6].
  • Hand-foot skin reaction (HFSR): Tazarotene may help prevent this side effect from certain cancer medications [7].
  • Postinflammatory erythema (PIE) and postinflammatory hyperpigmentation (PIH): These are skin discolorations that can occur after acne heals [8].
  • Nail psoriasis: Tazarotene has been studied for treating psoriasis affecting the nails [9].

Formulations and Strengths

Tazarotene is available in several formulations and strengths, allowing for tailored treatment approaches based on the condition being treated and individual patient factors:

  • Cream: Available in 0.05% and 0.1% strengths
  • Gel: Available in 0.05% and 0.1% strengths
  • Foam: Available in 0.1% strength
  • Lotion: Available in 0.045% and 0.1% strengths

Lower concentrations (0.045% or 0.05%) are often used for more sensitive skin or milder conditions, while higher concentrations (0.1%) may be prescribed for more severe cases [10].

Application Methods

How tazarotene is applied depends on the formulation and the specific condition being treated:

For Acne Vulgaris

  • Apply a thin layer to clean, dry skin once daily, typically in the evening
  • Some formulations (like DFD-03 lotion) may be applied twice daily for 1 minute and then rinsed off
  • Treatment areas typically include the entire face, avoiding the eyes, lips, and mucous membranes
  • Some patients may also apply to other affected areas such as the chest, back, and shoulders

For Plaque Psoriasis

  • Apply a thin film to cover only the affected areas once daily
  • Avoid application to unaffected skin
  • Follow your doctor’s instructions regarding how long to leave the medication on

Your healthcare provider will give you specific instructions based on your condition, the formulation prescribed, and your individual skin characteristics [11].

Efficacy in Treating Acne Vulgaris

Multiple clinical trials have demonstrated the effectiveness of tazarotene for acne vulgaris:

Impact on Acne Lesions

Studies show that tazarotene significantly reduces both inflammatory lesions (papules, pustules, and nodules) and non-inflammatory lesions (open and closed comedones) in patients with acne. In clinical trials, patients typically experienced:

  • Significant reduction in inflammatory lesion counts after 12 weeks of treatment
  • Significant reduction in non-inflammatory lesion counts after 12 weeks of treatment
  • Continued improvement with longer treatment duration

Global Assessment Improvement

Many patients achieve a clinical response of “success,” defined as an Investigator’s Global Assessment (IGA) score that is at least two grades less than the baseline assessment. This means their acne severity improved substantially during treatment [12].

Comparative studies have shown that tazarotene is effective in various formulations (cream, gel, foam, lotion), with newer formulations designed to minimize irritation while maintaining efficacy [13].

Efficacy in Treating Plaque Psoriasis

Tazarotene has demonstrated efficacy in treating plaque psoriasis in clinical studies:

Treatment Success Rates

In clinical trials, treatment success for psoriasis was defined as achieving a score of 0 (clear), 1 (minimal), or 2 (mild disease) on the Investigator’s Global Assessment (IGA) scale. Many patients achieved this level of improvement after 12 weeks of treatment [1].

Improvement in Psoriatic Features

Tazarotene helps improve specific features of psoriatic plaques:

  • Reduction in plaque elevation (thickness)
  • Decrease in scaling
  • Lessening of erythema (redness)

These improvements are measured using the Psoriasis Area Severity Index (PASI), with many patients achieving scores of 1 or less (indicating clear or almost clear) for these parameters after treatment [14].

Efficacy in Other Skin Conditions

Basal Cell Carcinoma and Basal Cell Nevus Syndrome

Research suggests that tazarotene may help as a chemopreventive agent for basal cell carcinomas (BCCs) in patients with basal cell nevus syndrome (BCNS). In one study, topical tazarotene was applied over 18 months, and researchers evaluated whether it reduced the incidence of BCCs on treated skin [4].

Brittle Nails

In a study of tazarotene for brittle nails, patients applied the medication twice daily to affected fingernails for 24 weeks. Improvements were measured in roughness, raggedness, and peeling of the nails [2].

Atrophic Post-Acne Scarring

Clinical research has compared tazarotene to other treatments like microneedling for atrophic post-acne scars. Some studies suggest that daily application of tazarotene gel 0.1% may help improve the appearance of certain types of acne scars [15].

Postinflammatory Erythema and Hyperpigmentation

Tazarotene is being studied for its potential to treat postinflammatory erythema (skin reddening) and postinflammatory hyperpigmentation (dark spots) that can occur after acne lesions heal. The lower concentration formulation (0.045%) may be beneficial in reducing these discolorations with less irritation than higher concentrations [8].

Potential Side Effects

As with any medication, tazarotene can cause side effects. Common side effects include:

Local Skin Reactions

  • Erythema (redness): May range from slight to moderate
  • Dryness: The skin may become dry with continued use
  • Peeling: Mild to moderate peeling of the skin is common
  • Burning or stinging: Especially when first applied
  • Itching: May occur in the treatment area

These side effects are typically most pronounced during the first few weeks of treatment and often decrease over time as your skin adjusts to the medication [16].

Less Common Side Effects

  • Skin irritation
  • Contact dermatitis
  • Temporary worsening of acne or psoriasis initially
  • Increased sensitivity to sunlight

If you experience severe irritation or an allergic reaction, discontinue use and contact your healthcare provider immediately [17].

Special Considerations

Sun Sensitivity

Tazarotene can make your skin more sensitive to sunlight. To protect your skin:

  • Limit sun exposure, especially between 10 AM and 2 PM
  • Use broad-spectrum sunscreen with SPF 30 or higher
  • Wear protective clothing, hats, and sunglasses
  • Avoid tanning beds and sunlamps

Pregnancy and Breastfeeding

Tazarotene is classified as pregnancy category X, meaning it should not be used during pregnancy as it may cause birth defects. Women of childbearing potential should use effective contraception during treatment. Discuss with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding [8].

Combination Therapy

Tazarotene is sometimes used in combination with other treatments for enhanced effectiveness:

  • For acne, it may be combined with topical antibiotics or benzoyl peroxide
  • For psoriasis, it may be used alongside corticosteroids or phototherapy

Your healthcare provider will determine the most appropriate treatment approach for your specific condition [18].

New Research Applications

Ongoing research is exploring new potential uses for tazarotene:

  • Treatment of idiopathic pulmonary fibrosis (IPF) with an oral formulation (GRI-0621)
  • Prevention of hand-foot skin reaction in cancer patients receiving certain medications
  • Treatment of postinflammatory pigmentation changes following acne

These applications are still being investigated in clinical trials and are not yet approved for routine clinical use [19].

Aspect Details
Primary Conditions Studied
  • Acne vulgaris (most common)
  • Plaque psoriasis
  • Basal cell skin cancer/nevus syndrome
  • Brittle nails
  • Cutaneous T-cell lymphoma
  • Post-inflammatory erythema and hyperpigmentation
  • Atrophic acne scars
Formulations Tested
  • Cream (0.05% and 0.1%)
  • Gel (0.05% and 0.1%)
  • Foam (0.1%)
  • Lotion (0.045% and 0.1%)
Application Methods
  • Most formulations: Once daily (often in the evening)
  • DFD-03 Lotion: Twice daily, applied for 1 minute then rinsed off
  • For acne: Applied to entire face
  • For psoriasis: Applied only to affected lesions
Efficacy Measurements
  • Reduction in inflammatory and non-inflammatory lesion counts
  • Improvement in Investigator’s Global Assessment (IGA) scores
  • For psoriasis: Improvement in Psoriasis Area Severity Index (PASI)
  • Subject satisfaction and quality of life measures
Common Side Effects
  • Erythema (redness)
  • Dryness
  • Peeling
  • Burning or stinging sensation
  • Itching
Comparative Studies
  • Tazarotene vs. adapalene for acne
  • Tazarotene + dapsone vs. tazarotene alone for acne
  • Tazarotene vs. microneedling for acne scars
  • Different formulations compared for local tolerability
Special Applications
  • Low concentration (0.045%) for sensitive skin
  • Short-contact application (1 minute) for reduced irritation
  • Oral form (GRI-0621) being studied for idiopathic pulmonary fibrosis
  • Used as a preventative treatment for hand-foot skin reactions during cancer therapy

FAQ

  • What skin conditions has tazarotene been studied for in clinical trials? Clinical trials have studied tazarotene for several skin conditions, with the most common being acne vulgaris and plaque psoriasis. It has also been investigated for basal cell skin cancer, basal cell nevus syndrome, brittle nails, cutaneous T-cell lymphoma, hand-foot skin reaction, and post-inflammatory erythema and hyperpigmentation. The medication has been tested in various formulations including creams, gels, foams, and lotions at different concentrations (primarily 0.05% and 0.1%).
  • How does tazarotene work to treat skin conditions? Tazarotene is a receptor-selective synthetic retinoid (vitamin A derivative) that works by normalizing skin cell differentiation and reducing inflammation. For acne, it helps prevent the formation of new acne lesions by regulating skin cell turnover and reducing the buildup of cells that can clog pores. In psoriasis, it helps normalize the accelerated skin cell growth that causes plaque formation. Tazarotene also has anti-inflammatory properties that help reduce redness and swelling associated with various skin conditions.
  • What are the common application methods for tazarotene in clinical trials? In clinical trials, tazarotene is typically applied once daily to affected areas, often in the evening. For acne, it's usually applied to the entire face. For psoriasis, it's applied directly to psoriatic plaques. Some newer formulations like tazarotene lotion 0.1% (DFD-03) are designed to be applied twice daily for just one minute and then rinsed off. The exact application instructions vary by formulation, concentration, and the condition being treated. Most trials instruct patients to apply a thin film or pea-sized amount to cover the treatment area.
  • What are the potential side effects of tazarotene observed in clinical trials? In clinical trials, common side effects of tazarotene included local skin reactions such as dryness, peeling, erythema (redness), burning or stinging sensation, and itching. These side effects were typically mild to moderate in severity and often decreased with continued use. Some studies allowed the use of moisturizers to manage dryness. More severe reactions were uncommon. Local tolerability assessments were regularly performed in trials to monitor these effects. Side effects were often more noticeable with higher concentrations (0.1% versus 0.05%) and formulations that remained on the skin longer.
  • How effective is tazarotene compared to other treatments in clinical trials? Clinical trials have compared tazarotene to other treatments and placebo controls. For acne, tazarotene has been compared with adapalene and has shown effectiveness in reducing both inflammatory and non-inflammatory lesions. Studies typically measure effectiveness by looking at reduction in lesion counts, improvement in investigator global assessment scores, and patient satisfaction. Tazarotene has consistently shown superiority over vehicle (placebo) controls in most trials. Some studies have also investigated combination approaches, such as using tazarotene with dapsone for acne, which may provide enhanced benefits compared to monotherapy.

Ongoing Clinical Trials on TAZAROTENE

  • Study on the Effects of IDP-118 Lotion (Tazarotene and Halobetasol Propionate) for Children with Moderate to Severe Plaque Psoriasis

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

Glossary

  • Acne Vulgaris: A common skin condition characterized by the presence of comedones (blackheads and whiteheads), papules, pustules, and sometimes nodules or cysts. It typically affects areas of the skin with many oil glands, such as the face, upper chest, and back.
  • Plaque Psoriasis: A chronic skin condition characterized by raised, red patches covered with a silvery white buildup of dead skin cells (scales). These patches often appear on the scalp, knees, elbows, and lower back.
  • Basal Cell Nevus Syndrome (BCNS): A rare genetic condition that causes multiple basal cell carcinomas (a type of skin cancer) to develop at an early age, along with other developmental abnormalities.
  • Tazarotene: A synthetic retinoid (vitamin A derivative) medication that is applied topically to treat various skin conditions by normalizing skin cell growth and reducing inflammation.
  • Investigator's Global Assessment (IGA): A standardized scale used by healthcare professionals in clinical trials to evaluate the overall severity of a skin condition. For acne, it typically ranges from 0 (clear) to 4 or 5 (severe).
  • Inflammatory Lesions: Acne lesions that are characterized by redness, swelling, and sometimes pain, including papules (small, solid, raised bumps), pustules (pus-filled bumps), and nodules (larger, deeper, solid bumps).
  • Non-inflammatory Lesions: Acne lesions that are not characterized by inflammation, including open comedones (blackheads) and closed comedones (whiteheads).
  • Psoriasis Area Severity Index (PASI): A tool used to measure the severity and extent of psoriasis, taking into account the redness, thickness, and scaling of lesions, as well as the percentage of body surface area affected.
  • Vehicle: In pharmaceutical terms, the base or carrier in which the active ingredient of a medication is dissolved or suspended. In clinical trials, vehicle-only formulations are often used as placebo controls.
  • Cutaneous T-Cell Lymphoma: A rare type of cancer that begins in white blood cells called T-cells that normally help the body fight infection. In cutaneous T-cell lymphoma, these cells become cancerous and affect the skin.
  • Erythema: Redness of the skin caused by increased blood flow to superficial capillaries. It can be a sign of inflammation or irritation.
  • Post-inflammatory Erythema (PIE): Pink or red discoloration that remains after an inflammatory acne lesion has healed. It is more common in lighter skin tones and is a temporary form of discoloration.
  • Post-inflammatory Hyperpigmentation (PIH): Darkening of the skin that occurs after an inflammatory wound or injury to the skin, such as acne. It is more common in darker skin tones.
  • Bioequivalence: A term used to describe when two medications with the same active ingredient have similar bioavailability and produce the same effect at the site of action in the body.
  • Pharmacokinetics: The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion.
  • Dermatology Life Quality Index (DLQI): A questionnaire used to measure the impact of skin diseases on a patient's quality of life.
  • Brittle Nails: A condition where nails chip, peel, or split excessively, occurring in up to 30% of women and 15% of men, with highest prevalence among the elderly.
  • Hand-Foot Skin Reaction (HFSR): A side effect of certain cancer treatments that causes redness, swelling, numbness, skin peeling or blistering on the palms of the hands and/or soles of the feet.
  • Microneedling: A cosmetic procedure that involves pricking the skin with tiny sterilized needles to generate new collagen and skin tissue for smoother, firmer, more toned skin, often used to treat acne scars.
  • Atrophic Acne Scars: Depressed scars that sit below the surrounding skin level, resulting from the destruction of collagen during the skin's inflammatory response to acne.

References

  1. https://clinicaltrials.gov/study/NCT02886702
  2. https://clinicaltrials.gov/study/NCT00648986
  3. https://clinicaltrials.gov/study/NCT02411955
  4. https://clinicaltrials.gov/study/NCT00489086
  5. https://clinicaltrials.gov/study/NCT05573425
  6. https://clinicaltrials.gov/study/NCT00779896
  7. https://clinicaltrials.gov/study/NCT04071756
  8. https://clinicaltrials.gov/study/NCT05704114
  9. https://clinicaltrials.gov/study/NCT02235480
  10. https://clinicaltrials.gov/study/NCT03292640
  11. https://clinicaltrials.gov/study/NCT03599193
  12. https://clinicaltrials.gov/study/NCT02886715
  13. https://clinicaltrials.gov/study/NCT02267746
  14. https://clinicaltrials.gov/study/NCT02160665
  15. https://clinicaltrials.gov/study/NCT03170596
  16. https://clinicaltrials.gov/study/NCT01017120
  17. https://clinicaltrials.gov/study/NCT01114841
  18. https://clinicaltrials.gov/study/NCT00834210
  19. https://clinicaltrials.gov/study/NCT06331624